Merrill Lynch Stick to Their Buy Rating for CVS Health Corp

Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, which is roughly 9.11 % above the present share price of $76.07.

Cherny expects CVS Health Corp to publish earnings per share (EPS) of $0.93 for the first quarter of 2021.

The present opinion among eleven TipRanks analysts is actually for a reasonable Buy rating of shares in CVS Health, with an average price target of $84.

The analysts priced targets range from a high of hundred one dolars to a low of $61.

From its latest earnings report, released on 09/30/2020, the company found a quarterly revenue of $67.06 billion and a net profit of $3.25 billion. The company’s market cap is actually $99.57 billion.

Based on TipRanks.com, Merrill Lynch analyst Michael Cherny is currently ranked with 4 stars on a 0 5 stars ranking scale, with an average return of 11.5 % as well as a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment provides pharmacy benefit management solutions. The Long or retail Term Care segment has offering of prescription drugs and assortment of general merchandise.

The Health Care Benefits segment offers traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioural health, medical control capabilities. The Corporate segment involves in providing management and administrative services. The company was developed by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.